Can a One-Time cell therapy reset the immune system in autoimmune disease?

NCT ID NCT07778446

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial is testing an experimental treatment called CRT-402 for people with severe autoimmune diseases like lupus, scleroderma, and myositis that haven't improved with standard therapies. CRT-402 is a type of CAR-T cell therapy given by infusion that aims to deplete certain immune cells (B cells) and potentially reset the immune system. The study will evaluate the safety, tolerability, and preliminary effectiveness of this approach in about 34 adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CRT-402, an in vivo CD19-targeted CAR-T cell therapy
What this could lead to
If successful, this could lead to a one-time treatment that resets the immune system, potentially offering long-term remission for people with severe autoimmune diseases.
What could go wrong
This is an early-stage trial, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome and neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Linear Advanced Clinical Trial Centre, Ground Floor, B Block, Queen Elizabeth II Medical Centre, Hospital Avenue

    Nedlands, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.